Global Lymphoma Antibodies Market & Clinical Trials Insight 2028

May 2022 | 420 pages | ID: G0B92A8E240BEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Lymphoma Antibodies Market & Clinical Trials Insight 2028” Report Highlights:

• Global Lymphoma Antibodies Market Opportunity: >USD 6 Billion
• Global Lymphoma Antibodies Market Insights: Current, Regional & Future Outlook 2028
• Annual, Quarterly & Regional Sales Insights On Lymphoma Antibodies
• Lymphoma Antibodies Availability By Dosage, Patent, & Price Analysis
• Clinical Insight On More Than 160 Lymphoma Antibodies In Trials
• Lymphoma Antibodies Clinical Trials Insights by Company, Country & Phase
• Annual, Quarterly & Regional Sales Insights On Lymphoma Antibodies

In last few years, remarkable progress has been made in the field of immunotherapy. Multiple immunotherapeutic approaches based on different targeting mechanism have emerged as standard treatment methodologies for the management of wide range of cancers, including lymphoma. Amid all approaches, antibody based immunotherapy is considered as main component of lymphoma therapy, alongside surgery, radiation, and chemotherapy. This is mainly attributed to several benefits associated with them in terms of specificity, selectivity, and targetability.

To date, several monoclonal antibodies have been approved for the management of lymphoma including Rituximab, Monjuvi, Keytruda, and others which have shown high adoption rates in the market. To further enhance their efficacy, researchers have developed antibody drug conjugates. Currently, three antibody drug conjugates namely Polivy, Adcetris, and Zynlonta have gained approval for the management of lymphoma. Since the entrance of these drugs, these have shown high adoption rates in the global market which has led to further research and development activities in this domain. Presently, more than 200 clinical trials are ongoing in global lymphoma antibody therapeutics market.

The advancement in the field of biotechnology and the robust research and development activities has led to introduction of next generation antibodies which are designed to be more potent and specific than conventional monoclonal antibodies. Although no bispecific antibody has entered the market, but it is suggested that it will hold a significant share in the forthcoming years which can be justified by the large number of ongoing clinical trials in this domain. For instance, Epcoritamab developed by Genmab's proprietary DuoBody technology is an investigational IgG1-bispecific antibody which is present in phase-I/II clinical trial. The preliminary results have demonstrated encouraging response in the management of relapsed/ refractory large B cell lymphoma.

The global lymphoma antibody therapeutics market is highly competitive and consists of several key players including Roche, Pfizer, ADC Therapeutics, Bristol Myers Squibb, and others. The companies have adopted strategic alliances injcluding partnership, collaboration, or joint ventures to maintain their position in the global market. Recently in 2021, Xencor and Janssen Biotech announced an exclusive collaboration and worldwide license agreement to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies which are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. The investigational Plamotamab is a XmAb bispecific antibody which targets CD20 and CD3 simultaneously. The drug is completing a Phase 1 dose-escalation study in patients with CD20-expressing non-Hodgkin lymphoma. Under the terms of the agreement, Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens.

As per our report findings, the global lymphoma antibody therapeutics market is expected to surpass US$ 6 Billion by 2028. The global lymphoma antibody therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL antibody therapeutics market is the major market among global lymphoma therapeutics market. The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth. Rising prevalence of lymphoma, increasing funding from different governments, growing awareness and accelerated approvals offered by the regulatory authorities are the other factors that would propel the market growth.

Lymphoma Antibodies Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report.

Contents

1. RESEARCH METHODOLOGY

2. GLOBAL LYMPHOMA ANTIBODY THERAPEUTICS MARKET

2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity

3. LYMPHOMA ANTIBODY DRUG CONJUGATES - AVAILABILITY, DOSAGE, PATENT, & PRICE ANALYSIS

3.1 Brentuximab Vedotin (Adcetris)
3.2 Polatuzumab vedotin (Polivy)
3.3 Loncastuximab Tesirine (Zynlonta)

4. LYMPHOMA MONOCLONAL ANTIBODIES - AVAILABILITY, PATENT, PRICE & DOSAGE ANALYSIS

4.1 Nivolumab (Opdivo)
4.2 Tafasitamab (Monjuvi/Minjuvi)
4.3 Rituximab (Mabthera/Rituxan)
4.4 Rituximab Biosimilar (Truxima)
4.5 Rituximab Biosimilar (Riabni)
4.6 Rituximab Biosimilar (Ruxience)
4.7 Rituximab/Hyaluronidase (Rituxan Hycela)
4.8 Obinutuzumab (Gazyva)
4.9 Pembrolizumab (Keytruda )
4.10 Sintilimab (Tyvyt)
4.11 Camrelizumab (AiRuiKa)
4.12 Tislelizumab (Baize’an)
4.13 Zimberelimab
4.14 Penpulimab

5. LYMPHOMA ANTIBODY DRUG CONJUGATES – GLOBAL & REGIONAL SALES ANALYSIS

5.1 Adcetris
5.2 Polivy
5.3 Zynlonta

6. LYMPHOMA MONOCLONAL ANTIBODIES - GLOBAL & REGIONAL SALES ANALYSIS

6.1 Opdivo
6.2 Monjuvi
6.3 Rituxan
6.4 Gazvya
6.5 Keytruda

7. GLOBAL LYMPHOMA ANTIBODIES CLINICAL TRIALS OVERVIEW

7.1 By Company
7.2 By Country
7.3 By Phase
7.4 By Patient Segment

8. GLOBAL LYMPHOMA ANTIBODIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered

9. MARKETED LYMPHOMA ANTIBODIES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

10. COMPETITIVE LANDSCAPE

10.1 AbbVie
10.2 ADC Therapeutics
10.3 BeiGene
10.4 Bristol Myers Squibb
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Merck
10.8 Morphosys
10.9 Ono Pharmaceutical
10.10 Pfizer
10.11 Roche
10.12 Seagen
10.13 Takeda Pharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 2-1: Global – Hodgkin Lymphoma Incidences & Deaths (Million), 2020 & 2030
Figure 2-2: Global – Non- Hodgkin Lymphoma Incidences & Deaths (Million), 2020 & 2030
Figure 2-3: Global – Lymphoma Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-4: Global - Lymphoma Antibodies Therapeutics Market Size by Product Value (%), 2021
Figure 2-5: Global – Lymphoma Antibodies Therapeutics Market Size by Region (US$ Million), 2021
Figure 2-6: Global – Lymphoma Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-7: Global – Lymphoma Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: US - Adcetris Oprhan Drug Designation Approval Year by Indication
Figure 3-2: US - Adcetris FDA Approval Year by Indication
Figure 3-3: Adcetris - Approval Year by Region
Figure 3-4: Japan - Adcetris FDA Approval Year by Indication
Figure 3-5: Adcetris - Patent Expiration by Region
Figure 3-6: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), May’2022
Figure 3-7: Adcetris - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 3-8: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 3-9: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), May’2022
Figure 3-10: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 3-11: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), May’2022
Figure 3-12: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), January'2022
Figure 3-13: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 3-14: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), January'2022
Figure 3-15: Polivy - Orphan Drug Designation Approval Year by Region
Figure 3-16: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 3-17: Polivy - Approval Year by Region
Figure 3-18: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), May’2022
Figure 3-19: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), May’2022
Figure 3-20: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 3-21: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of DLBCL (US$), May’2022
Figure 3-22: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 3-23: US - Zynlonta Orphan Drug Designation & FDA Approval Year
Figure 3-24: Zynlonta - Orphan Drug Designation by Region
Figure 3-25: Zynlonta – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2022
Figure 3-26: Zynlonta – Recommended Dose for Initial & Subsequent Cycles (mg/kg)
Figure 4-1: Opdivo – Approval Year by Region
Figure 4-2: Opdivo – FDA Approval by Indication
Figure 4-3: Opdivo - Patent Expiration Year by Region
Figure 4-4: US - Price for 4ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-5: US - Price for 10 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-6: US - Price for 12 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-7: US - Price for 24 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-8: UK - Price for 4 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-9: UK - Price for 10ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-10: UK - Price for 24ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-11: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), May’2022
Figure 4-12: Tafasitamab – Approval Year by Region
Figure 4-13: Monjuvi – Number of Dose per Treatment Cycle by Phase
Figure 4-14: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 4-15: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), May’2022
Figure 4-16: Rituxan – FDA Approval Year by Indication
Figure 4-17: MabThera – Approval Year by Region
Figure 4-18: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 4-19: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 4-20: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US$), May’2022
Figure 4-21: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 4-22: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 4-23: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), May’2022
Figure 4-24: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 4-25: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 4-26: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), May’2022
Figure 4-27: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-28: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US$), May’2022
Figure 4-29: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), May’2022
Figure 4-30: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 4-31: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 4-32: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 4-33: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), February’2022
Figure 4-34: Ruxience – Approval Year by Region
Figure 4-35: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 4-36: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 4-37: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-38: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-39: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), February’2022
Figure 4-40: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), May’2022
Figure 4-41: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), May’2022
Figure 4-42: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 4-43: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US$), May’2022
Figure 4-44: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (weeks)
Figure 4-45: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US$), May’2022
Figure 4-46: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), May’2022
Figure 4-47: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 4-48: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), May’2022
Figure 4-49: Gazyva – Approval Year by Cancer Type
Figure 4-50: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US$), May’2022
Figure 4-51: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of Lymphoma (mg)
Figure 4-52: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week)
Figure 4-53: Gazyva – Cost of Initial & Subsequent Treatment Cycle of Lymphoma (US$), May’2022
Figure 4-54: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), February’2022
Figure 4-55: Keytruda – Approval Year by Region
Figure 4-56: Keytruda – FDA Approval Year by Indication
Figure 4-57: Keytruda – Patent Expiration Year by Region
Figure 4-58: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), May’2022
Figure 4-59: UK - Price for 4ml & Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), May’2022
Figure 4-60: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), May’2022
Figure 4-61: Tyvyt – NMPA Approval by Indication
Figure 4-62: China– Price for Vial of AiRuiKa (Yuan/US$), May’2022
Figure 4-63: Tislelizumab – NMPA Approval by Indication
Figure 4-64: China– Price for Vial of Penpulimab (Yuan/US$), May’2022
Figure 5-1: Global - Adcetris Quarter 1 Sales (US$ Million), 2021 & 2022
Figure 5-2: Global - Adcetris Annual Sales (US$ Million), 2018 - 2021
Figure 5-3: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 5-4: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 5-5: Polivy – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 5-6: Global - Polivy Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-7: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-8: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-9: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-10: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 5-11: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-12: Polivy - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-13: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 5-14: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-15: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-16: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-17: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 5-18: Polivy - Annual Sales Value by Region (%), 2020
Figure 5-19: Polivy – Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 5-20: Global - Zynlonta Quarterly Sales (US$ Million), Q2 & Q3'2021
Figure 6-1: Global - Opdivo Quarter 1 Sales Value by Region (US$ Million), 2022
Figure 6-2: Global - Opdivo Quarter 1 Sales Value by Region (%), 2022
Figure 6-3: Global - Opdivo Annual Sales Value (US$ Million), 2018-2021
Figure 6-4: US - Opdivo Annual Sales Value (US$ Million), 2018-2021
Figure 6-5: Global – Opdivo Annual Sales Value by Region (US$ Million), 2021
Figure 6-6: Global - Opdivo Annual Sales Value by Region (%), 2021
Figure 6-7: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 6-8: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 6-9: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 6-10: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 6-11: US - Monjuvi Annual Sales Value (US$ Million), 2020 & 2021
Figure 6-12: US - Monjuvi Quarterly Sales Value (US$ Million), 2021
Figure 6-13: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 & Q4, 2020
Figure 6-14: Polivy – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 6-15: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-16: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-17: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-18: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-19: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-20: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 6-21: Rituxan - Annual Sales Value by Region (%), 2021
Figure 6-22: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 6-23: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 6-24: Polivy – Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 6-25: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-26: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 6-27: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-28: Global - Adcetris Quarter 1 Sales (US$ Million), 2021 & 2022
Figure 6-29: Global - Keytruda Annual Sales Value (US$ Billion), 2018 - 2021
Figure 6-30: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 6-31: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 7-1: Global Lymphoma Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 7-2: Global Lymphoma Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 7-3: Global Lymphoma Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 7-4: Global Lymphoma Antibodies in Clinical Trials by Patient Segment, 2022 till 2028